Recently launched and relatively small Avista Therapeutics Inc. has just cut a deal with comparatively massive Roche Holding AG that could bring the new Pittsburgh-based company more than $1 billion. Avista’s single cell adeno-associated virus (AAV) platform will be used to develop intravitreal AAV capsids that match a Roche-defined capsid profile. Roche will evaluate and license Avista’s capsids and conduct the preclinical, clinical and commercialization work for the gene therapy programs. Read More
New interim data from Ultragenyx Pharmaceutical Inc. and Genetx Biotherapeutics LLC’s phase I/II study of GTX-102 in Angelman’s syndrome didn’t do much to bolster investor confidence, as Ultragenyx shares sagged considerably July 19. The Novato, Calif.-based company’s stock (NADAQ:RARE) closed 13% downward at $52.89 per share. That is nearly half the price shares fetched in late August. At $102.40 per share, that was the stock’s highest value in the past 12 months. Read More
Although it’s a latecomer to the COVID-19 pandemic in the U.S., there is a wedge of opportunity for Novavax Inc.’s adjuvanted protein-based vaccine among the 10% of the U.S. adult population that has yet to get a first jab. Read More
Oxford Science Enterprises, an independent investor specializing in building companies through its relationship with the U.K.’s University of Oxford, has raised a further £250 million (US$300 million) to translate academic research into commercial products and businesses. Read More
Qiming Venture Partners has closed funds worth a total $3.2 billion for health care-related investments, with funds spread across the five areas of biopharmaceuticals, med tech, diagnostics, health care services and IT. Read More
The U.S. CMS released the draft Medicare hospital outpatient rule for calendar year 2023, a document that is replete with information on pass-through payment data for drugs and devices. However, the agency said that the Supreme Court’s ruling regarding rates for drugs covered under the 340B drug pricing program came too late in the annual cycle to be fully accounted for in the outpatient rule for 2023, and thus any such permanent adjustments will have to wait until the outpatient rule for 2024. Read More
In this multipart special report, BioWorld explores the concept of extending lifespan, which is surprisingly well-validated by basic research. The team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing these potential “Fountain of Youth” candidate drugs. Read More
In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clene, Eledon, Eliem, Iveric, Maia, Mei, Mindbloom, Olipass, Prometheus, Seelos, Sesen. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amylyx, Bavarian, Erasca, GSK, HLB, Lee’s Merck & Co., PMV, Purespring, Regenerx, Swanbio, Unicycive. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Acer, Alzamend, Byondis, Calliditas, Entera, Eton, Relief, Rhythm, Stuart, Sumitomo. Read More